Novel metabolic biomarkers of cardiovascular disease

Nature Reviews Endocrinology

Volumn 10, Issue 11, 2014, Pages 659-672

  Jensen, Majken K ^a   Bertoia, Monica L ^a   Cahill, Leah E ^a   Agarwal, Isha ^a   Rimm, Eric B ^b   Mukamal, Kenneth J ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Beth Israel Deaconess Medical Centre   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADIPONECTIN; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 23; HAPTOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LIPOPROTEIN A; VITAMIN D; 25-HYDROXYVITAMIN D; FIBROBLAST GROWTH FACTOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN METABOLISM; META ANALYSIS (TOPIC); MINERAL METABOLISM; NONHUMAN; PARTICLE SIZE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANALOGS AND DERIVATIVES; CORONARY ARTERY DISEASE; METABOLISM;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADIPONECTIN; BIOLOGICAL MARKERS; CORONARY DISEASE; FIBROBLAST GROWTH FACTORS; HAPTOGLOBINS; HEMOGLOBIN A, GLYCOSYLATED; HOMOCYSTEINE; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS, HDL; VITAMIN D;

EID: 84908141562     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2014.155     Document Type: Review

References (197)

1. Roger V. L. et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125, e2-e220(2012).
2. Prosser L. A . et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann. Intern. Med. 132, 769-779 (2000).
3. Goff D. C. et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, S49-S73 (2014).
4. Ridker P. M., Buring J. E., Cook N. R. & Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulatio n 107, 391-397 (2003).
5. NIH. Third report of the National Cholesterol Education Program (NECP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report [online], http://www.nhlbi.nih.gov/files/docs/resources/heart/atp3full.pdf (2004).
6. Gordon T., Castelli W. P., Hjortland M. C., Kannel W. B. & Dawber T. R. High d ensity lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62, 707-714 (1977).
7. McQueen M. J. et al. Lipids, lipoproteins, and apolipoproteins as ris k markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study Lancet 372 224-233 2008).
8. Di Angelantonio E. et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993-2000 (2009).
9. Sniderman A. D. et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ. Cardiovasc. Qual. Outcomes 4, 337-345 (2011).
10. Corti R. et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two y ears' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 106, 2884-2887 (2002).
11. Grundy S. M. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227-239 (2004).
12. West A. M. et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis 218, 156-162 (2011).
13. Cannon C. P. et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am. Heart J. 156, 826-832 (2008).
14. Superko H. R. & King S. III. Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 117, 560-568 (2008).
15. Grundy S. M. Promise of low-density lipoprotein-lowering therapy for primary and secondary prevention. Circulation 117, 569-573 (2008).
16. Anuurad E., Boffa M. B., Koschinsky M. L. & Berglund L. Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin. Lab. Med. 26, 751-772 (2006).
17. Hobbs H. H. & White A. L. Lipoprotein(a): intrigues and insights. Curr. Opin. Lipidol. 10, 225-236 (1999).
18. Marcovina S. M. & Koschinsky M. L. Lipoprotein(a) as a risk factor for coronary artery disease. Am. J. Cardiol. 82, 57U-66U (1998).
19. Poon M., Zhang X., Dunsky K. G., Taubman M. B. & Harpel P. C. Apolipoprotein(a) induces monocyte chemotactic activity in human vascu lar endothelial cells. Circulation 96, 2514-2519 (1997).
20. Nielsen L. B., Gronholdt M. L., Schroeder T. V., Stender S. & Nordestgaard B. G. In vivo transfer of lipoprotein(a) int o human atherosclerotic carotid arterial intima. Arterioscler. Thromb. Vasc. Biol. 17, 905-911 (1997).
21. Helgadottir A. et al. Apolipoprotein(a) genetic sequence variants associated with systemic at herosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J. Am. Coll. Cardiol. 60, 722-729 (2012).
22. Nielsen L. B., Juul K. & Nordestgaard B. G. Increa sed degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: in vivo evidence that lipoprotein(a) may contribute to foam cell formation. Arterioscler. Thromb. Vasc. Biol. 18, 641-649 (1998).
23. Danik J. S. et al. Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21,483 women. J. Thromb. Haemost. 11, 205-208 (2013).
24. Erqou S. et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302, 412-423 (2009).
25. Nordestgaard B. G. et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34, 3478a-3490a (2013).
26. Boerwinkle E. et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J. Clin. Invest. 90, 52-60 (1992).
27. Mooser V. et al. The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans. Am. J. Hum. Genet. 61, 402-417 (1997).
28. Tregouet D. A. et al Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat. Genet.41 283-285 2009).
29. Kamstrup P. R., Tybj aerg-Hansen A., Steffensen R. & Nordestgaard B. G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301, 2331-2339 (2009).
30. Holmer S. R. et al. Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation 107, 696-701 (2003).
31. Insull W. Jr et al. Efficacy of exte nded-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch. Intern. Med. 164, 1121-1127 (2004).
32. Albers J. J. et al. R elationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes). J. Am. Coll. Cardiol. 62, 1575-1579 (2013).
33. Bregar U., Jug B., Keber I., Cevc M. & Sebestjen M. Extended-release niacin/laropiprant improves endothelial function in patients after myocardial inf arction. Heart Vessels 29, 313-319 (2013).
34. Bruckert E., Labreuche J. & Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210, 353-361 (2010).
35. HSP2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laro piprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 34, 1279-1291 (2013).
36. Takagi H. & Umemoto T. Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials. Int. J. Cardiol. 154, 183-186 (2012).
37. Maher V. M. et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 274, 1771-1774 (1995).
38. Berg K. et al. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin. Genet. 52, 254-261 (1997).
39. Merki E. et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J. Am. Coll. Cardiol. 57, 1611-1621 (2011).
40. Merki E. et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice . Circulation 118, 743-753 (2008).
41. Kolski B. & Tsimikas S. Emerging therapeutic agents to lower lipoprotein (a) levels. Curr. Opin. Lipidol. 23, 560-568 (2012).
42. Taleb A., Witztum J. L. & Tsimikas S. Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomar k. Med. 5, 673-694 (2011).
43. Bertoia M. L. et al. Oxidation-specific biomarkers and risk of peripheral artery disease. J. Am. Coll. Cardiol. 61, 2169-2179 (2013).
44. Ozkanlar S. & Akcay, F. Antioxidant vitamins in atherosclerosis-animal experiments and clinical studies. Adv. Clin. Exp. Med. 21, 115-123 (2012).
45. Schaloske R. H. & Dennis E. A. The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta 1761, 1246-1259 (2006).
46. Asano K. et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem. Biophys. Res. Commun. 261, 511-514 (1999).
47. Tsimihodimos V. et al. Atorvastatin preferentially reduces LDL-associated platelet-activati ng factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler. Thromb. Vasc. Biol. 22, 306-311 (2002).
48. Stafforini D. M., Prescott S. M. & McIntyre T. M. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J. Biol. Chem. 262, 4223-4230 (1987).
49. Zalewski A. & Macphee C. Role of lipoprotein-associated phospholipase A 2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler. Thromb. Vasc. Biol. 25, 923-931 (2005).
50. Rosenson R. S. Stafforini D. M.Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2 J. Lipid Res.53 1767-1782 2012).
51. Vittos O., Toana B., Vittos A. & Moldoveanu E. L ipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker. Biomarkers 17, 289-302 (2012).
52. Ali M. & Madjid M. Lipoprotei n-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target. Future Cardiol. 5, 159-173 (2009).
53. McConnell J. P. & Hoefner D. M. Lipoprotein-associated phospholipase A2. Clin. Lab. Med. 26, 679-697 (2006).
54. Mallat Z., Lambeau G. & Tedgui A. Lipoprotein-associated and secreted phospholipases A(2) in cardiovascular disease: roles as bio logical effectors and biomarkers. Circulation 122, 2183-2200(2010).
55. Mohler E. R. III et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the res ults of a multicenter, randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 51, 1632-1641 (2008).
56. White H. D. et al. Darapladib for preventing ischemic events in stable coronary heart disease. N. Engl. J. Med. 370, 1702-1711 (2014).
57. Rosenson R. S. et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation 128, 1256-1267 (2013).
58. Movva R. & Rader D. J. Laboratory assessment of HDL heterogeneity and function. Clin. Chem. 54, 788-800 (2008).
59. Nissen S. E. et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304-1316 (2007).
60. Barter P. J. et al. Effects of to rcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007).
61. Briel M. et al. Association between change in high density lipoprotein cholesterol and cardiovascula r disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338, b92 (2009).
62. McPherson R. et al. A common allele on chromosome 9 associated with coronary heart disease. Science 316, 1488-1491 (2007).
63. Willer C. J. et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40, 161-169 (2008).
64. Aulchenko Y. S. et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat. Genet. 41, 47-55 (2009).
65. Voight B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380, 572-580 (2012).
66. de Souza J. A. et al. Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis 197, 84-94 (2008).
67. Onat A., Can. G., Ayhan E., Kaya Z. & Hergenc G. Impaired protection against diabetes and coronary heart disease by high-density lipoproteins in Turks. Metabolism 58, 1393-1399 (2009).
68. Wilkins J. T. et al. Coronary heart disease risks associated with high levels of HDL cholesterol. J. Am. Heart Assoc. 3, e000519 (2014).
69. Khera A. V. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127-135 (2011).
70. Li X. M. et al. Parado xical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler. Thromb. Vasc. Biol. 33, 1696-1705 (2013).
71. Asztalos B. F. et al High-density lip oprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol. 24 2181-2187 2004).
72. Mora S. et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 119, 931-939 (2009).
73. Pa rish S. et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 125, 2469-2478 (2012).
74. Stampfer M. J., Sacks, F. M. , Salvini S., Willett W. C. & Hennekens C. H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N. Engl. J. Med. 325, 373-381 (1991).
75. Willia ms P. T. & Feldman D. E. Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort. Atherosclerosis 214, 196-202 (2011).
76. van der Steeg W. A. et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll.Cardiol. 51, 634-642 (2008).
77. Schwartz G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089-2099 (2012).
78. Rubins H. B. e t al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341, 410-418 (1999).
79. Asztalos B. F. et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler. T hromb. Vasc. Biol. 25, 2185-2191 (2005).
80. Asztalos B. F. et al. Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affai rs High-Density Lipoprotein Intervention Trial. Metabolism 57, 77-83 (2008).
81. Alaupovic P. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Methods Enzymol. 263, 32-60 (1996).
82. Shah A. S., Tan L., Long J. L. & Davidson W. S. Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J. Lipid Res. 54, 2575-2585 (2013).
83. Huang Y. et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat. Med. 20, 193-203 (2014).
84. Jensen M. K., Rimm E. B., Furtado J. D. & Sacks, F. M. Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart d isease. J. Am. Heart Assoc. 1, jah3-e000232 (2012).
85. Mendivil C. O., Rimm E. B., Furtado J., Chiuve S. E. & Sacks, F. M. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation 124, 2065-2072 (2011).
86. Jensen M. K., Furtado J. D., Rimm E. B., Sacks, F. M. & Overvad K. Presence of apolipoprotein C-III defines a high density lipoprotein subtype that is not inversely associated with incident coronary events [abstract 023]. Circulation 127 (Suppl. 12), A023 (2013).
87. Kawakami A. et al. Apolip oprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 113, 691-700 (2006).
88. Graham M. J. et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ. Res. 112, 1479-1490 (2013).
89. Splaver A., Lamas G. A. & Henneken s C. H. Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials. Am. Heart J. 148, 34-40 (2004).
90. McCully K. S. Vascular patholog y of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am. J. Pathol. 56, 111-128 (1969).
91. Boushey C. J., Beresford S. A., Omenn G. S. & Motulsky A. G. A quanti tative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274, 1049-1057 (1995).
92. Yang Q. et al. Improvement in stroke mortality in Canada and the United States 1990 to 2002. Circulation 113 1335-1343 2006).
93. Strain J. J., Dowey L., Ward M., Pentieva K. & McNulty H. B-vitamins, homocysteine metabolism and CVD. Proc. Nutr. Soc. 63, 597-603 (2004).
94. Clarke R. et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mo rtality: Meta-analysis of 8 randomized trials involving 37,485 individuals. Arch. Intern. Med. 170, 1622-1631 (2010).
95. Wang X. et al. Eff icacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369, 1876-1882 (2007).
96. Saposnik G., Ray J. G., Sheridan P., McQueen M. & Lonn E. Homocyst eine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 40, 1365-1372 (2009).
97. Wang L., Manson J. E., Song Y. & Sesso H. D. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann. Intern. Med. 152, 315-323 (2010).
98. Holick M. F. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am. J. Clin. Nutr. 79, 362-371 (2004).
99. Bikle D. D. et al. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J. Clin. Endocrinol. Metab. 63, 954-959 (1986).
100. Bikle D. D., Siiteri P. K., Ryzen E. & Haddad J. G. Serum protein binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels. J. Clin. Endocrinol. Metab. 61, 969-975 (1985).
101. Lou Y.R. et al. 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. J. Steroid Biochem. Mol. Biol. 118, 162-170 (2010).
102. Dobnig H. et al. Independent associa tion of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 168, 1340-1349 (2008).
103. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog. Biophys. Mol. Biol. 92, 39-48 (2006).
104. Zehnder D. et al. Synthesis of 1,25-dihydroxyvitamin D3 by human endothelial cells is regulat ed by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J. Am. Soc. Nephrol. 13, 621-629 (2002).
105. Brø ndum-Jacobsen P., Benn M., Jensen G. B. & Nordestgaard B. G. 25-hydroxyvitamin D levels and risk of ischemic heart disease, myocardial infarction, and early death: population-based study and meta-analyses of 18 and 17 studies. Arterioscler. Thromb. Vasc. Biol. 32, 2794-2802 (2012).
106. Sokol S. I., Tsang P., Aggarwal V., Melamed M. L. & Srinivas V. S. Vitamin D status and risk of cardiovascular events: lessons learned via systematic review and meta-analysis. Cardiol. Rev. 19, 192-201 (2011).
107. Wang L. et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ. Cardiovasc. Qual. Outcomes 5, 819-829 (2012).
108. Grandi N. C., Breitling L. P. & Brenner H. Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies. Prev. Med. 51, 228-233 (2010).
109. Forman J. P. et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49, 1063-1069 (2007).
110. Mattil a C. et al. Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care 30, 2569-2570 (2007).
111. Shea M. K. et al. Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am. J. Epidemiol. 167, 313-320(2008).
112. Tomson J. e t al. Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12,000 deaths. Eur. Heart J. 34, 1365-1374 (2013).
113. Marco M. P. et al. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int. Suppl. 85, S111-S114 (2003).
114. Naves-Diaz M. et al.i Oral active vitamin D is associated with improved survival in hemodialysis patients Kidney Int. 74 1070-1078 2008).
115. Shoji T. et al. Lower risk for cardiovascular mortality in oral 1'-hydroxy vitamin D3 users in a haemodialysis population. Nephrol. Dial. Transplant. 19, 179-184 (2004).
116. Teng M. et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. 16, 1115-1125 (2005).
117. Wolf M. et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 72, 1004-1013 (2007).
118. Hsia J. et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 115, 846-854 (2007).
119. Forman J. P. et al. Effect of vitamin D supplementation on blood pressure in blacks. Hypertension. 61, 779-785 (2013).
120. Shimada T. et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone. Miner. Res. 19, 429-435 (2004).
121. Gutierrez O. M. et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119, 2545-2552 (2009).
122. Gutierrez O. M. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 359, 584-592 (2008).
123. Isakova T. et al. Fibrobla st growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305, 2432-2439 (2011).
124. Mirza M. A., Larsson A., Melhus H., Li nd L. & Larsson T. E. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207, 546-551 (2009).
125. Parker B. D. et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann. Intern. Med. 152, 640-648 (2010).
126. Seiler S. et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur. Heart J. 32, 2688-2696 (2011).
127. Faul C. et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393-4408 (2011).
128. Shalhoub V. et al. FGF23 neutrali zation improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J. Clin. Invest. 122, 2543-2553 (2012).
129. Touchberry C. D. et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am. J. Physiol. Endocrinol. Metab. 304, E863-E873 (2013).
130. Dominguez J. R., Shlipak M. G., Whooley M. A. & Ix J. H. Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes. J. Am. Soc. Nephrol. 24, 647-654 (2013).
131. Oh D. K., Ciaraldi T. & Henry R. R. Adiponectin in health and disease. Diabetes Obes. Metab. 9, 282-289 (2007).
132. Stefan N. & Stumvoll M. Adiponectin-its role in metabolism and beyond. Horm. Metab. Res. 34, 469-474 (2002).
133. Li S., Shin H. J., Ding E. L. & van Dam R. M. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302, 179-188 (2009).
134. Hotta K. et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50, 1126-1133 (2001).
135. Ouchi N. et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocy te-derived macrophages Circulation 103 1057-1063 2001).
136. Pischon T. et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291, 1730-1737 (2004).
137. Sattar N. et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114, 623-629 (2006).
138. Lindsay R. S. et al. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler. Thromb. Vasc. Biol. 25, e15-e16 (2005).
139. Heidemann C. et al. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann. Intern. Med. 149, 307-316 (2008).
140. Pischon T. et al. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women. Atherosclerosis 219, 322-329 (2011).
141. Kizer J. R. et al. Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults. J. Clin. Endocrinol. Metab. 98, 255-263 (2013).
142. Rathmann W. & Herder C. Adipo nectin and cardiovascular mortality: evidence for " reverse epidemiology" . Horm. Metab. Res. 39, 1-2 (2007).
143. Wilson S. R. et al. Assessment of adiponectin and the risk of recurrent cardi ovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am. Heart J. 161, 1147-1155 (2011).
144. Onat A., Hergenc G., Can. G. & Kucukdurmaz Z. Serum adiponectin confers little protection against diabetes and hypertension in Turkish men. Obesity (Silver Spring) 17, 564-570 (2009).
145. Menzaghi C. et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 51, 2306-2312 (2002).
146. ADIPOGen Consortium [online], http://www.mcgill.ca/genepi/adipogen-consortium (2014).
147. CARDIoGRAMplusC4D Consortium [online], http://www.cardiogramplusc4d.org (2013).
148. Dastani Z. et al. The shared allelic architecture of adiponectin levels and coronary artery disease. Atherosclerosis 229, 145-148 (2013).
149. Ki ssebah A. H. et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc. Natl Acad. Sci. USA 97, 14478-14483 (2000).
150. Dastani Z. et al. N ovel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet. 8, e1002607 (2012).
151. Kadowaki T. et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116, 1784-1792 (2006).
152. Coppola A. et al. Effect of weight loss on coronary circulation and adiponectin levels in obese women. Int. J. Cardiol. 134, 414-416 (2009).
153. Selvin E. et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N. Engl. J. Med. 362, 800-811 (2010).
154. Selvin E. et al. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch. Intern. Med. 165, 1910-1916 (2005).
155. Pradhan A. D., Rifai N., Buring J. E. & Ridker P. M. Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am. J. Med. 120, 720-727 (2007).
156. Khaw K. T. et al Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann. Intern. Med.141 413-4202004).
157. Adams R. J. et al. Independent association of HbA1c and incident cardiovascular disease in people without diabetes. Obesity (Silver Spring) 17, 559-563 (2009).
158. Lawlor D. A., Fraser A., Ebrahim S. & Smith G. D. Independent associations of fasting insulin, glucose, and glycated haemoglobin with stroke and coronary heart disease in older women. PLoS Med. 4, e263 (2007).
159. Pai J. K. et al. Hemoglobin a1c is associated with increased risk of incident coronary heart disease among apparently healthy, nondiabetic men and women. J. Am. Heart Assoc. 2, e000077 (2013).
160. Blake G. J. et al. Hemoglobin A1c level and future cardiovascular events among women. Arch. Intern. Med. 164, 757-761 (2004).
161. Sarwar N. et al. Markers of dysglycaemia and r isk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med. 7, e1000278 (2010).
162. Sarwar N. et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375, 2215-2222 (2010).
163. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32, 1327-1334 (2009).
164. Gerstein H. C. Glycosylated hemoglobin: finally ready for prime time as a cardiovascular risk factor. Ann. Intern. Med. 141, 475-476 (2004).
165. Marshall S. M. & Barth J. H. Standardization of HbA1c measurements-A consensus statement. Diabet. Med. 17, 5-6 (2000).
166. Sander D. et al. Combined effects of hemoglobin A1c and C-reactive protein on the progression of subclinical carotid atherosclerosis: the INVADE study. Stroke 37, 351-357 (2006).
167. Vlassara H., Brownlee M., Manogue K. R., Dinarello C. A. & Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240, 1546-1548 (1988).
168. King D. E., Mainous A. G. III, Buchanan T. A. & Pearson W. S. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care 26, 1535-1539 (2003).
169. Verma S. et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106, 913-919 (2002).
170. Giugliano D. et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 95, 1783-1790 (1997).
171. Gerstein H. C. More insights on the dysglycaemia-cardiovascular connection. Lancet 375, 2195-2196 (2010).
172. Gerstei n H. C. & Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet 347, 949-950 (1996).
173. Emerging Risk Factors Collaboration. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA 311, 1225-1233 (2014).
174. Knowler W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002).
175. Orchard T. J. et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann. Intern. Med. 142, 611-619 (2005).
176. Ratner R. et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 28, 888-894 (2005).
177. Li G. et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2, 474-480 (2014).
178. Gerstein H. C. et al Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J.Med. 358 2545-2559 2008).
179. Wright E. E. Jr., Stonehouse A. H. & Cuddihy R. M. In support of an early polypharmacy approach to the treatment of type 2 diabetes. Diabetes Obes. Metab. 12, 929-940 (2010).
180. Tuomilehto J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343-1350 (2001).
181. Lindstrom J. et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368, 1673-1679 (2006).
182. [No authors listed] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837-853 (1998).
183. Patel A. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560-2572 (2008).
184. Duckworth W. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129-139 (2009).
185. Levy A. P. et al. Hapto globin: basic and clinical aspects. Antioxid. Redox Signal. 12, 293-304 (2010).
186. Cahill L. E. et al. Currently available versions of genome-wide association studies cannot be used to query the common haptoglobin copy number variant. J. Am. Coll. Cardiol. 62, 860-861 (2013).
187. Langlois M. R. & Delanghe J. R. Biological and clinical significance of haptoglobin polymorphism in humans. Clin. Chem. 42, 1589-1600 (1996).
188. Levy A. P. et al. Hap toglobin phenotype and prevalent coronary heart disease in the Framingham offspring cohort. Atherosclerosis 172, 361-365 (2004).
189. De Bacquer D. et al. Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. Atherosclerosis 157, 161-166 (2001).
190. Asleh R., Guetta J., Kalet-Litman S., Miller-Lotan R. & Levy A. P. Haptoglobin genotype-and d iabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ. Res. 96, 435-441 (2005).
191. Asleh R. et al. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ. Res. 99, 1419-1425 (2006).
192. Asleh R. et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ. Res. 92, 1193-1200(2003).
193. Cahill L. E. et al. Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J. Am. Coll. Cardiol. 61, 728-737 (2013).
194. Levy A. P. et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J. Am. Coll. Cardiol. 40, 1984-1990 (2002).
195. Gerstein H. C. et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N. Engl. J. Med. 364, 818-828 (2011).
196. Carter K. & Worwood M. Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. Int. J. Lab. Hematol. 29, 92-110 (2007).
197. Vickers A. J. & Pepe M. Does the net reclassification improvement help us evaluate models and markers? Ann. Intern. Med. 160, 136-137 (2014).